Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Motor Activity 12Breast Neoplasms 9Neoplasms 6Leukemia, Myeloid, Acute 3Prostatic Neoplasms 2Patient Compliance 2Neoplasm Metastasis 2Fatigue 2Depression 2Colorectal Neoplasms 2Brain Neoplasms 2Weight Loss 1Weight Gain 1Smoking Cessation 1Peripheral Nervous System Diseases 1Overweight 1Ovarian Neoplasms 1Obesity 1Neuroectodermal Tumors, Primitive 1Medulloblastoma 1Lung Neoplasms 1Insulin Resistance 1Infratentorial Neoplasms 1Fallopian Tube Neoplasms 1Disease 1Cognitive Dysfunction 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bone Metabolism Biomarkers 1Body Weight Changes 1

Interventions

Vincristine 1Saline Solution 1Radiotherapy 1Pemetrexed 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Cisplatin 1Bupivacaine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Infratentorial Neoplasms × Exercise × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡